Lowest Price Guaranteed From USD 4,799
Published
February 2023
Pages
140
View Count
10440
Example Insights
Please scroll down
Report Description
Viral clearance market (testing services) was estimated to be USD 545 million in 2023 and is anticipated to grow at a CAGR of 10% during the forecast period. Viral clearance testing refers to the detection and elimination of viral contaminants, using a wide array of methods, to ensure the product’s safety for human use. Over the past few years, viral clearance testing has emerged as one of the key pre-requisites for biopharmaceutical regulatory approvals. It is worth mentioning that, till date, over 630 biologics have already been approved by the Food and Drug Administration (FDA), while more than 8,000 biopharmaceuticals are in the clinical evaluation process. This increased number of approvals and ongoing clinical trials in the biopharmaceutical industry has resulted in a rise in the demand for such studies. However, virus removal, viral inactivation and virus detection requires specialized expertise as it is a complex, cost intensive, and time consuming process. Therefore, innovators are actively exploring avenues that would enable them to overcome the existing challenges. Among other alternatives, outsourcing these studies to service providers having FDA accredited laboratories has emerged as a preferred option for most of the biopharmaceutical manufacturers. Presently, a number of service providers across the globe are actively engaged in providing efficient viral clearance testing services throughout the research and development process. Further, as more biologics enter into the development pipeline, the viral clearance market size (services) is anticipated to witness a healthy CAGR during the forecast period.
The Viral Clearance Market - Distribution by Scale of Operation (Discovery Phase, Preclinical Phase and Clinical Phase), Method of Viral Clearance Testing (Viral Detection, Viral Inactivation and Viral Removal), End User (Biotechnology and Pharmaceutical Companies and Academic / Research Institutes) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunity for the laboratories involved in offering viral clearance testing services. The report answers many key questions related to this industry.
 |
 |
 |
Viral clearance studies have emerged as a mandatory step for regulatory submissions of biologics for commercial applications. These studies result in streamlined manufacturing of contamination free / safe products and on-time delivery of biologics. Owing to this, the demand for these services has increased significantly. It is worth highlighting that, with the continuous revision of the regulatory guidelines, viral clearance studies are already amongst the most essential steps in the manufacturing of biologics, including antibodies, blood products, cell and gene therapies, hormones, recombinant proteins, therapeutic proteins and vaccines.
The rise of biologics has resulted in an increasing demand for viral clearance testing services. However, these studies are quite cost intensive, time-consuming and follow stringent regulatory guidelines. In addition, they require specialized technical skills and good scientific expertise. This has prompted the biopharmaceutical developers to outsource the viral clearance studies to the service providers, which have aseptic laboratories, GMP-certified facilities and specialized equipment in accordance with the requirements of regulatory authorities.
The viral clearance testing service providers landscape features a mix of large, mid-sized and small companies, which have the required expertise to offer various services for the viral clearance and testing of biologics, across the manufacturing and purification n stages. It is worth highlighting that majority of the service providers are large companies. Recent developments in this segment of the biopharmaceutical industry indicate that the service providers are upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for these services.
 |
 |
 |
Since the onset of the COVID-19 pandemic, viral clearance testing services for biopharmaceuticals have garnered significant attention. In addition, the success of next generation sequencing in efficiently detecting a wide variety of viruses has created an enormous need for the consistent usage of such advanced tools / methods in viral clearance and testing studies. In the coming decade, several promising techniques, specifically those exhibiting enhanced efficacy, are anticipated to develop at a faster rate. Moreover, considering the active involvement of large players as well as the new entrants, the viral clearance testing services market is likely to witness healthy growth during the forecast period.
Further, to address the growing demand for these services, various large players have undertaken several initiatives, including strengthening their respective service portfolios, entering into strategic deals, and expanding their facility and capacity. The most recent collaboration was signed between France based GTP Bioways and Texcell in March 2023. The former is a CDMO for biologic manufacturing and Texcell is a CRO specializing in viral testing, viral clearance and bioassays. The partnership has created a one-stop solution for their clients, specifically biopharmaceutical companies for testing and manufacturing support during clinical development.
Viral clearance market for testing services was estimated to be USD 545 million in 2023. Driven by the rising interest in research and development activities and the demand for viral clearance testing services, the future opportunities and growth associated with this market are anticipated to witness a noteworthy growth in the foreseen future. The global market is anticipated to grow at a CAGR of 10% during the forecast period. Specifically, in terms of end users, the market is anticipated to be driven by biotechnology and pharmaceutical companies. In addition, presently, more than 60% of the market is captured by laboratories based in North America and Europe. Asia-pacific is being looked at as a growth market for the viral clearance testing services, as the development and manufacturing of biologics and biosimilars is picking up in countries such as China and India. MilliporeSigma opened a biologics testing center in Shanghai, China in September 2022. The center has a viral clearance laboratory, set-up with the aim to meet the growing local demand for viral clearance testing services.
 |
 |
Presently, viral removal dominates the viral clearance testing services market. This can be attributed to the ongoing innovations and advancements in viral removal techniques, such as chromatography, filtration, and precipitation. Viral inactivation involves the inactivation of viruses using physical or chemical methods. A number of laboratory supply companies are developing novel medium and reagents for inactivation of virus, supporting the viral inactivation methods. Additionally, the growing number of marketed and pipeline biologics such as cell and gene therapy, tissue and tissue products and vaccines, will continue to support the demand for viral inactivation service market.
Examples of key companies engaged in this industry (which have also been captured in this report) include Charles River Laboratories, Creative Biolabs, Eurofins Scientific, Microbac Laboratories, MilliporeSigma, Nelson Labs, Syngene International, Texcell, Vironova and WuXi Biologics.
Several recent developments have taken place in the field of viral clearance market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments as defined in the below table:
| Key Report Attributes | Details | |
|
Base Year |
2022 |
|
|
Forecast Period |
2023-2035 | |
|
Market Size 2023 |
$545 million | |
|
CAGR 2023-2035 |
10% | |
|
Scale of Operation |
Discovery Phase, Preclinical Phase, Clinical Phase | |
|
Method of Viral Clearance and Testing |
Viral Detection, Viral Inactivation, Viral Removal |
|
|
End-User |
Biotechnology and Pharmaceutical Companies, Academic / Research Institutes | |
| Key Geographical Regions | North America, Europe, Asia-Pacific, Rest of the World | |
| Key Companies Profiled |
Charles River Laboratories, Eurofins Scientific, Microbac Laboratories, Nelson Labs, Pall, Syngene International, Texcell |
|
| Customization Scope |
15% Free Customization Option (equivalent to 5 analysts working days) |
|
| PowerPoint Presentation (Complimentary) | Available | |
| Excel Data Packs (Complimentary) | Market Landscape Analysis, Company Competitiveness Analysis, Patent Analysis, Recent Developments, Market Forecast and Opportunity Analysis | |
The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market, across different geographies. Amongst other elements, the market report includes:
One of the key objectives of the market report was to estimate the current opportunity and the future growth potential of the viral clearance testing services market over the forecast period. We have provided informed estimates on the likely evolution of the market for the period, 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as scale of operation (discovery phase, preclinical phase and clinical phase), method of viral clearance and testing (viral detection, viral inactivation and viral removal), end user (biotechnology and pharmaceutical companies and academic / research institutes), and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Chapter Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3 INTRODUCTION
3.1. Chapter Overview
3.2. Viral Contamination in Biologics
3.3. Need for Viral Clearance and Testing
3.4. Process of Viral Clearance and Testing
3.5. Regulatory Guidelines Related to Viral Contamination
3.6. Future Perspectives
4. VIRAL CLEARANCE TESTING SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Viral Clearance Testing Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters (Region)
4.2.5. Analysis by Location of Viral Clearance Testing Facilities
4.2.6. Analysis by Type of Virus Detected (by Envelope)
4.2.7. Analysis by Type of Virus Detected (by Class)
4.2.8. Analysis by Key Offerings
4.2.9 Analysis by Type of Biologic(s) Analyzed
4.2.10 Analysis by Method(s) of Viral Clearance (Inactivation)
4.2.11 Analysis by Method(s) of Viral Clearance (Removal)
4.2.12 Analysis by Type of Viral Testing Service(s) Offered
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2 Methodology and Key Parameters
5.3. Viral Clearance Testing Service Providers in North America
5.4. Viral Clearance Testing Service Providers in Europe
5.5. Viral Clearance Testing Service Providers in Asia-Pacific and Rest of the World
6. VIRAL CLEARANCE TESTING SERVICE PROVIDERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Charles River Laboratories
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Viral Clearance and Testing Related Services
6.2.4. Recent Developments and Future Outlook
6.3. Microbac Laboratories
6.3.1. Company Overview
6.3.2. Viral Clearance and Testing Related Services
6.3.3. Recent Developments and Future Outlook
6.4. Nelson Labs (subsidiary of Sotera Health)
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Viral Clearance and Testing Related Services
6.4.4. Recent Developments and Future Outlook
6.5. Pall (subsidiary of Danaher)
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Viral Clearance and Testing Related Services
6.5.4. Recent Developments and Future Outlook
7. VIRAL CLEARANCE TESTING SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC
7.1. Chapter Overview
7.2. Eurofins Scientific
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Viral Clearance and Testing Related Services
7.2.4. Recent Developments and Future Outlook
7.3. Syngene International
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Viral Clearance and Testing Related Services
7.3.4. Recent Developments and Future Outlook
7.4. Texcell
7.4.1. Company Overview
7.4.2. Viral Clearance and Testing Related Services
7.4.3. Recent Developments and Future Outlook
8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Viral Clearance Testing: Patent Analysis
8.3.1. Analysis by Patent Publication Year
8.3.2. Analysis by Patent Applications
8.3.3. Analysis by Type of Patent and Patent Publication Year
8.3.4. Analysis by Type of Organization
8.3.5. Word Cloud Analysis: Emerging Focus Areas
8.3.6. Analysis by Geography
8.3.7. Analysis by CPC Symbols
8.3.8. Leading Players: Analysis by Number of Patents
8.4. Viral Clearance Testing : Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.5. Viral Clearance and Testing Services: Patent Valuation Analysis
8.6. Leading Patents by Number of Citations
9. RECENT DEVELOPMENTS
9.1 Chapter Overview
9.2. Partnerships and Collaborations
9.2.1. Partnership Models
9.2.2. Viral Clearance Testing Service Providers: List of Partnerships and Collaborations
9.2.3. Analysis by Year of Partnership
9.2.4. Analysis by Type of Partnership
9.2.5. Analysis by Year and Type of Partnership
9.2.6. Analysis by Purpose of Partnership
9.2.7. Analysis by Type of Organization
9.2.8. Analysis by Location of Facility (Country)
9.2.9. Analysis by Location of Facility (Region)
9.2.10. Most Active Players: Analysis by Number of Partnerships
9.2.11. Analysis by Geography
9.2.11.1. Intercontinental and Intracontinental Agreements
9.3. Recent Expansions
9.3.1. Viral Clearance Testing Service Providers: List of Recent Expansions
9.3.2. Analysis by Year of Expansion
9.3.3. Analysis by Type of Expansion
9.3.4. Analysis by Focus of Expansion
9.3.5. Analysis by Type of Service(s) Offered
9.3.6. Analysis by Type of Biologic(s) Involved
9.3.7. Analysis by Type of Expansion and Biologic(s) Involved
9.3.8. Most Active Players: Analysis by Number of Expansions
9.3.9. Analysis by Geography
10. VIRAL CLEARANCE TESTING SERVICES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Viral Clearance Market, 2023-2035
10.3.1. Global Viral Clearance Market: Distribution by Scale of Operation, 2023 and 2035
10.3.1.1. Viral Clearance Market for Discovery Phase, 2023-2035
10.3.1.2. Viral Clearance Market for Preclinical Phase, 2023-2035
10.3.1.3. Viral Clearance Market for Clinical Phase, 2023-2035
10.3.2. Global Viral Clearance Market: Distribution by Method of Viral Clearance and Testing, 2023 and 2035
10.3.2.1. Viral Clearance Market for Viral Detection, 2023-2035
10.3.2.2. Viral Clearance Market for Viral Inactivation, 2023-2035
10.3.2.3. Viral Clearance Market for Viral Removal, 2023-2035
10.3.3. Global Viral Clearance Market: Distribution by End-User, 2023 and 2035
10.3.3.1. Viral Clearance Market for Biotechnology and Pharmaceutical Companies, 2023-2035
10.3.3.2. Viral Clearance Market for Academic / Research Institutes, 2023-2035
10.3.4. Global Viral Clearance Market: Distribution by Key Geographical Regions, 2023 and 2035
10.3.4.1. Viral Clearance Market in North America, 2023-2035
10.3.4.2. Viral Clearance Market in Europe, 2023-2035
10.3.4.3. Viral Clearance Market in Asia-Pacific, 2023-2035
10.3.4.4. Viral Clearance Market in Rest of the World, 2023-2035
11. CONCLUSION
12. EXECUTIVE INSIGHTS
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1. Executive Summary: Overall Market Landscape
Figure 2.2. Executive Summary: Patent Analysis
Figure 2.3. Executive Summary: Recent Developments
Figure 2.4. Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1. Sources of Viral Contamination
Figure 3.2. Process of Viral Clearance and Testing
Figure 4.1. Viral Clearance Testing Service Providers: Distribution by Year of Establishment
Figure 4.2. Viral Clearance Testing Service Providers: Distribution by Company Size
Figure 4.3. Viral Clearance Testing Service Providers: Distribution by Location of Headquarters
Figure 4.4. Viral Clearance Testing Service Providers: Distribution by Company Size and Location of Headquarters (Region)
Figure 4.5. Viral Clearance Testing Service Providers: Distribution by Location of Viral Clearance and Testing Facilities
Figure 4.6. Viral Clearance Testing Service Providers: Distribution by Type of Virus Detected (by Envelope)
Figure 4.7. Viral Clearance Testing Service Providers: Distribution by Type of Virus Detected (by Class)
Figure 4.8. Viral Clearance Testing Service Providers: Distribution by Key Offerings
Figure 4.9. Viral Clearance Testing Service Providers: Distribution by Type of Biologic(s) Analyzed
Figure 4.10. Viral Clearance Testing Service Providers: Distribution by Method(s) of Viral Clearance (Inactivation)
Figure 4.11. Viral Clearance Testing Service Providers: Distribution by Method(s) of Viral Clearance (Removal)
Figure 4.12. Viral Clearance Testing Service Providers: Distribution by Type of Viral Testing Service(s) Offered
Figure 5.1. Competitiveness Analysis of Viral Clearance Testing Service Providers in North America
Figure 5.2. Competitiveness Analysis of Viral Clearance Testing Service Providers in Europe
Figure 5.3. Competitiveness Analysis of Viral Clearance Testing Service Providers in Asia-Pacific and Rest of the World
Figure 6.1. Charles River Laboratories: Annual Revenues, 2017-9M 2022 (USD Billion)
Figure 6.2. Nelson Labs: Annual Revenues, 2019-9M 2022 (USD Million)
Figure 6.3. Danaher (parent company of Pall): Annual Revenues, 2017-9M 2022 (USD Billion)
Figure 7.1. Eurofins Scientific: Annual Revenues, 2017-9M 2022 (EUR Billion)
Figure 7.2. Syngene International: Annual Revenues, FY 2018-FY H1 2023 (INR Billion)
Figure 8.1. Patent Analysis: Distribution by Type of Patent
Figure 8.2. Patent Analysis: Cumulative Distribution by Patent Publication Year, 2017-2022
Figure 8.3. Patent Analysis: Cumulative Distribution of Patent Applications, Pre- 2017-2022
Figure 8.4. Patent Analysis: Distribution by Type of Patent and Patent Publication Year, 2017-2022
Figure 8.5. Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, 2017-2022
Figure 8.6. Patent Analysis: Emerging Focus Areas
Figure 8.7. Patent Analysis: Distribution by Geography
Figure 8.8. Patent Analysis: Distribution by CPC Symbols
Figure 8.9. Patent Analysis: Leading Players
Figure 8.10. Patent Analysis (Leading Players): Benchmarking by Patent Characteristics (CPC Symbols)
Figure 8.11. Patent Analysis: Distribution of Patents by Age
Figure 8.12. Viral Clearance Testing: Patent Valuation
Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2022
Figure 9.4. Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 9.5. Partnerships and Collaborations: Distribution by Type of Organization, 2015-2022
Figure 9.6. Partnerships and Collaborations: Distribution by Location of Facility (Country)
Figure 9.7. Partnerships and Collaborations: Distribution by Location of Facility (Region)
Figure 9.8. Most Active Players: Distribution by Number of Partnerships
Figure 9.9. Partnerships and Collaborations: Distribution by Geography
Figure 9.10. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.11. Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Figure 9.12. Recent Expansions: Distribution by Type of Expansion
Figure 9.13. Recent Expansions: Distribution by Focus of Expansion
Figure 9.14. Recent Expansions: Distribution by Type of Service(s) Offered
Figure 9.15. Recent Expansions: Distribution by Type of Biologic(s) Involved
Figure 9.16. Recent Expansions: Distribution by Type of Expansion and Service(s) Offered
Figure 9.17. Recent Expansions: Distribution by Type of Expansion and Biologic(s) Involved
Figure 9.18. Most Active Players: Distribution by Number of Expansions
Figure 9.19. Recent Expansions: Distribution by Geography
Figure 9.20. Recent Expansions: Distribution by Location of Expansion Project
Figure 10.1. Global Viral Clearance Market, 2023-2035 (USD Million)
Figure 10.2. Viral Clearance Market: Distribution by Scale of Operation, 2023 and 2035 (USD Million)
Figure 10.3. Viral Clearance Market for Discovery Phase, 2023-2035 (USD Million)
Figure 10.4. Viral Clearance Market for Preclinical Phase, 2023-2035 (USD Million)
Figure 10.5. Viral Clearance Market for Clinical Phase, 2023-2035 (USD Million)
Figure 10.6. Viral Clearance Market: Distribution by Method of Viral Clearance and Testing, 2023 and 2035 (USD Million)
Figure 10.7. Viral Clearance Market for Viral Detection, 2023-2035 (USD Million)
Figure 10.8. Viral Clearance Market for Viral Inactivation, 2023-2035 (USD Million)
Figure 10.9. Viral Clearance Market for Viral Removal, 2023-2035 (USD Million)
Figure 10.10. Viral Clearance Market: Distribution by End-User, 2023 and 2035 (USD Million)
Figure 10.11. Viral Clearance Market for Biotechnology and Pharmaceutical Companies, 2023-2035 (USD Million)
Figure 10.12. Viral Clearance Market for Academic / Research Institutes, 2023-2035 (USD Million)
Figure 10.13. Viral Clearance Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Figure 10.14. Viral Clearance Market in North America, 2023-2035 (USD Million)
Figure 10.15. Viral Clearance Market in Europe, 2023-2035 (USD Million)
Figure 10.16. Viral Clearance Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 10.17. Viral Clearance Market in Rest of the World, 2023-2035 (USD Million)
Figure 11.1. Concluding Remarks: Overall Market Landscape
Figure 11.2. Concluding Remarks: Patent Analysis
Figure 11.3. Concluding Remarks: Recent Developments
Figure 11.4. Concluding Remarks: Market Sizing and Opportunity Analysis
Table 4.1. Viral Clearance Testing Service Providers: Information on Company, Year of Establishment, Company Size, Location of Headquarters and Location of Viral Clearance Testing Service Facilities
Table 4.2. Viral Clearance Testing Service Providers: Information on Type of Virus Detected (by Envelope) and Type of Virus Detected (by Class)
Table 4.3. Viral Clearance Testing Service Providers: Information on Key Offerings and Type of Biologic(s) Analyzed
Table 4.4. Viral Clearance Testing Service Providers: Information on Method(s) of Viral Clearance (Inactivation), Method(s) of Viral Clearance (Removal) and Type of Viral Testing Service(s) Offered
Table 6.1. Viral Clearance Testing Service Providers in North America: List of Companies Profiled
Table 6.2. Charles River Laboratories: Company Snapshot
Table 6.3. Charles River Laboratories: Overview of Viral Clearance and Testing Services
Table 6.4. Charles River Laboratories: Recent Developments and Future Outlook
Table 6.5. Microbac Laboratories: Company Snapshot
Table 6.6. Microbac Laboratories: Overview of Viral Clearance and Testing Services
Table 6.7. Nelson Labs: Company Snapshot
Table 6.8. Nelson Labs: Overview of Viral Clearance and Testing Services
Table 6.9. Nelson Labs: Recent Developments and Future Outlook
Table 6.10. Pall Corporation: Company Snapshot
Table 6.11. Pall Corporation: Overview of Viral Clearance and Testing Services
Table 7.1. Viral Clearance Testing Service Providers in Europe and Asia-Pacific: List of Companies Profiled
Table 7.2. Eurofins Scientific: Company Snapshot
Table 7.3. Eurofins Scientific: Overview of Viral Clearance and Testing Services
Table 7.4. Eurofins Scientific: Recent Developments and Future Outlook
Table 7.5. Syngene International: Company Snapshot
Table 7.6. Syngene International: Overview of Viral Clearance and Testing Services
Table 7.7. Syngene International: Recent Developments and Future Outlook
Table 7.8. Texcell: Company Snapshot
Table 7.9. Texcell: Overview of Viral Clearance and Testing Services
Table 7.10. Texcell: Recent Developments and Future Outlook
Table 8.1. Patent Analysis: CPC Sections
Table 8.2. Patent Analysis: CPC Codes
Table 8.3. Patent Analysis: CPC Symbol
Table 8.4. Patent Analysis: Summary of Benchmarking Analysis
Table 8.5. Patent Analysis: Categorization based on Weighted Valuation Scores
Table 8.6. Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 8.7. Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 9.1. Viral Clearance Testing Service Providers: List of Partnerships and Collaborations, 2015-2022
Table 9.2. Partnerships and Collaborations: Information on Purpose of Partnership, Type of Organization, Location of Facility (Country) and Location of Facility (Region), 2015-2022
Table 9.3. Viral Clearance Testing Service Providers: List of Recent Expansions, 2017-2022
Table 9.4. Recent Expansions: Information on Type of Service(s) Offered and Type of Biologic(s) Involved, 2017-2022
Table 12.1. hylabs: Company Snapshot
Table 12.2. WuXi Biologics: Company Snapshot
Table 13.1. Viral Clearance Testing Service Providers: Distribution by Year of Establishment
Table 13.2. Viral Clearance Testing Service Providers: Distribution by Company Size
Table 13.3. Viral Clearance Testing Service Providers: Distribution by Location of Headquarters
Table 13.4. Viral Clearance Testing Service Providers: Distribution by Company Size and Location of Headquarters (Region)
Table 13.5. Viral Clearance Testing Service Providers: Distribution by Type of Virus Detected (by Envelope)
Table 13.6. Viral Clearance Testing Service Providers: Distribution by Type of Virus Detected (by Class)
Table 13.7. Viral Clearance Testing Service Providers: Distribution by Key Offerings
Table 13.8. Viral Clearance Testing Service Providers: Distribution by Type of Biologic(s) Analyzed
Table 13.9. Viral Clearance Testing Service Providers: Distribution by Method(s) of Viral Clearance (Inactivation)
Table 13.10. Viral Clearance Testing Service Providers: Distribution by Method(s) of Viral Clearance (Removal)
Table 13.11. Viral Clearance Testing Service Providers: Distribution by Type of Viral Testing Service(s) Offered
Table 13.12. Charles River Laboratories: Annual Revenues, 2017-9M 2022 (USD Billion)
Table 13.13. Nelson Labs: Annual Revenues, 2019-9M 2022 (USD Million)
Table 13.14. Danaher (parent company of Pall): Annual Revenues, 2017-9M 2022 (USD Billion)
Table 13.15. Eurofins Scientific: Annual Revenues, 2017-9M 2022 (EUR Billion)
Table 13.16. Syngene International: Annual Revenues, FY 2018-FY H1 2023 (INR Billion)
Table 13.17. Patent Analysis: Distribution by Type of Patent
Table 13.18. Patent Analysis: Cumulative Distribution by Patent Publication Year, 2017-2022
Table 13.19. Patent Analysis: Cumulative Distribution of Patent Applications, Pre- 2017-2022
Table 13.20. Patent Analysis: Distribution by Type of Patent and Patent Publication Year, 2017-2022
Table 13.21. Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, 2017-2022
Table 13.22. Patent Analysis: Emerging Focus Areas
Table 13.23. Patent Analysis: Distribution by Geography
Table 13.24. Patent Analysis: Distribution by CPC Symbols
Table 13.25. Patent Analysis: Leading Players
Table 13.26. Patent Analysis (Leading Players): Benchmarking by Patent Characteristics (CPC Symbols)
Table 13.27. Patent Analysis: Distribution of Patents by Age
Table 13.28. Viral Clearance Testing: Patent Valuation
Table 13.29. Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Table 13.30. Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.31. Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2022
Table 13.32. Partnerships and Collaborations: Distribution by Purpose of Partnership
Table 13.33. Partnerships and Collaborations: Distribution by Type of Organization, 2015-2022
Table 13.34. Partnerships and Collaborations: Distribution by Location of Facility (Region)
Table 13.35. Most Active Players: Distribution by Number of Partnerships
Table 13.36. Partnerships and Collaborations: Distribution by Geography
Table 13.37. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 13.38. Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Table 13.39. Recent Expansions: Distribution by Type of Expansion
Table 13.40. Recent Expansions: Distribution by Focus of Expansion
Table 13.41. Recent Expansions: Distribution by Type of Service(s) Offered
Table 13.42. Recent Expansions: Distribution by Type of Biologic(s) Involved
Table 13.43. Recent Expansions: Distribution by Type of Expansion and Service(s) Offered
Table 13.44. Recent Expansions: Distribution by Type of Expansion and Biologic(s) Involved
Table 13.45. Most Active Players: Distribution by Number of Expansions
Table 13.46. Recent Expansions: Distribution by Geography
Table 13.47. Recent Expansions: Distribution by Location of Expansion Project
Table 13.48. Global Viral Clearance Market: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.49. Viral Clearance Market: Distribution by Scale of Operation, 2023 and 2035 (USD Million)
Table 13.50. Viral Clearance Market for Discovery Phase: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.51. Viral Clearance Market for Preclinical Phase: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.52. Viral Clearance Market for Clinical Phase: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.53. Viral Clearance Market: Distribution by Method of Viral Clearance and Testing, 2023 and 2035 (USD Million)
Table 13.54. Viral Clearance Market for Viral Detection: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.55. Viral Clearance Market for Viral Inactivation: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.56. Viral Clearance Market for Viral Removal: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.57. Viral Clearance Market: Distribution by End-User, 2023 and 2035 (USD Million)
Table 13.58. Viral Clearance Market for Biotechnology and Pharmaceutical Companies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.59. Viral Clearance Market for Academic / Research Institutes: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.60. Viral Clearance Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 13.61. Viral Clearance Market in North America: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.62. Viral Clearance Market in Europe: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.63. Viral Clearance Market in Asia-Pacific: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.64. Viral Clearance Market in Rest of the World: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
The following companies and organizations have been mentioned in the report:
Source 1: https://www.phrma.org/science-and-discovery/in-the-pipeline
Source 2: https://www.fda.gov/about-fda/fda-basics/fact-sheet-fda-glance
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES